

# ASX Release

---

## HC Berlin Pharma Update

**PERTH, AUSTRALIA – 29 March 2018:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, provides an update to the matter with HC Berlin Pharma.

On 27 February 2017, the Company provided an update on a closed hearing held on 20 January 2017 in the German courts and also stated that SUDA had initiated an Appeal against the recent court judgement. As outlined in the Annual Report, the Appeal was lodged in August 2017.

The Appeal was heard this month and the Company received verbal notification that the Appeal has been dismissed. There have been no written findings from the court.

The Directors are not in a position to finalise the next step in this process until the written judgement and legal clarification have been received, however, it is anticipated that a further Appeal will be lodged.

SUDA's CEO, Mr Stephen Carter, commented: "The outcome of the Appeal was not unexpected and we continue to review and consider all options available through the German legal system. We also maintain the ability for further discussions with the Receiver."



**Further information:**

**STEPHEN CARTER**

**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**

**SUDA Pharmaceuticals Ltd**

Tel: +61 8 6142 5555

[sjcarter@sudapharma.com](mailto:sjcarter@sudapharma.com)

## **NOTES TO EDITORS:**

### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine.

Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit [www.sudapharma.com](http://www.sudapharma.com)